Similar articles for PMID: 20645876

Year	Number of Results
1986	1
1995	1
1998	2
1999	2
2000	1
2002	1
2004	4
2005	2
2006	3
2007	5
2008	3
2009	5
2010	8
2011	6
2012	3
2013	8
2014	5
2015	5
2016	6
2017	8
2018	7
2019	11
2020	7
2021	2
2022	2
2023	1
2024	0

1

Interferon-lambda as a potential therapeutic agent in cancer treatment.

Steen HC, Gamero AM. Steen HC, et al. J Interferon Cytokine Res. 2010 Aug;30(8):597-602. doi: 10.1089/jir.2010.0058. J Interferon Cytokine Res. 2010. PMID: 20645876 Free PMC article. Review.

2

A possible anticancer agent, type III interferon, activates cell death pathways and produces antitumor effects.

Tagawa M, Kawamura K, Li Q, Tada Y, Hiroshima K, Shimada H. Tagawa M, et al. Clin Dev Immunol. 2011;2011:479013. doi: 10.1155/2011/479013. Epub 2011 Oct 16. Clin Dev Immunol. 2011. PMID: 22013482 Free PMC article. Review.

3

Interferon-lambda: a new addition to an old family.

Donnelly RP, Kotenko SV. Donnelly RP, et al. J Interferon Cytokine Res. 2010 Aug;30(8):555-64. doi: 10.1089/jir.2010.0078. J Interferon Cytokine Res. 2010. PMID: 20712453 Free PMC article. Review.

4

Novel type III interferons produce anti-tumor effects through multiple functions.

Li Q, Kawamura K, Tada Y, Shimada H, Hiroshima K, Tagawa M. Li Q, et al. Front Biosci (Landmark Ed). 2013 Jun 1;18(3):909-18. doi: 10.2741/4152. Front Biosci (Landmark Ed). 2013. PMID: 23747856 Free article. Review.

5

IFN-λ cancer immunotherapy: new kid on the block.

Lasfar A, Gogas H, Zloza A, Kaufman HL, Kirkwood JM. Lasfar A, et al. Immunotherapy. 2016 Jul;8(8):877-88. doi: 10.2217/imt-2015-0021. Immunotherapy. 2016. PMID: 27381684 Free PMC article. Review.

6

Interferons: Success in anti-viral immunotherapy.

Lin FC, Young HA. Lin FC, et al. Cytokine Growth Factor Rev. 2014 Aug;25(4):369-76. doi: 10.1016/j.cytogfr.2014.07.015. Epub 2014 Jul 29. Cytokine Growth Factor Rev. 2014. PMID: 25156421 Free PMC article. Review.

7

Interferon lambda as a potential new therapeutic for hepatitis C.

Miller DM, Klucher KM, Freeman JA, Hausman DF, Fontana D, Williams DE. Miller DM, et al. Ann N Y Acad Sci. 2009 Dec;1182:80-7. doi: 10.1111/j.1749-6632.2009.05241.x. Ann N Y Acad Sci. 2009. PMID: 20074277

8

Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.

Busnadiego I, Fernbach S, Pohl MO, Karakus U, Huber M, Trkola A, Stertz S, Hale BG. Busnadiego I, et al. mBio. 2020 Sep 10;11(5):e01928-20. doi: 10.1128/mBio.01928-20. mBio. 2020. PMID: 32913009 Free PMC article.

9

Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons.

Pfeffer LM, Dinarello CA, Herberman RB, Williams BR, Borden EC, Bordens R, Walter MR, Nagabhushan TL, Trotta PP, Pestka S. Pfeffer LM, et al. Cancer Res. 1998 Jun 15;58(12):2489-99. Cancer Res. 1998. PMID: 9635566 Review.

10

Interferon lambda: a new sword in cancer immunotherapy.

Lasfar A, Abushahba W, Balan M, Cohen-Solal KA. Lasfar A, et al. Clin Dev Immunol. 2011;2011:349575. doi: 10.1155/2011/349575. Epub 2011 Dec 6. Clin Dev Immunol. 2011. PMID: 22190970 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

101 results

Results by year